Summary by Futu AI
Merck & Co., Inc., a leading pharmaceutical company, reported its first-quarter financial results for 2024 on April 25, 2024. The company announced a 9% increase in total worldwide sales to $15.8 billion compared to the first quarter of 2023, with a 12% growth excluding the impact of foreign exchange. Oncology and vaccines were significant contributors to the growth, with KEYTRUDA sales rising 20% to $6.9 billion and GARDASIL/GARDASIL 9 sales increasing 14% to $2.2 billion. The company's GAAP EPS was $1.87, while non-GAAP EPS was $2.07, both including a charge for the acquisition of Harpoon Therapeutics. Merck also received FDA approval for WINREVAIR, a treatment for adults with pulmonary arterial hypertension, and made progress in other therapeutic areas. The company raised its full-year 2024 financial outlook, expecting worldwide sales to be between $63.1 billion and $64.3 billion and non-GAAP EPS to be between $8.53 and $8.65. The report was signed by Corporate Secretary Kelly E. W. Grez.